A 12 Week Study to Evaluate the Efficacy of an Eye Cream
Launched by REVISION SKINCARE · Mar 29, 2023
Trial Information
Current as of September 18, 2025
Completed
Keywords
ClinConnect Summary
This single center, open-label clinical study was conducted to evaluate the efficacy and tolerability of an eye cream on healthy female subjects between 35 to 60 years of age with Fitzpatrick Skin Type I - VI, and moderate to severe dark circles and under-eye puffiness. This study aims to evaluate the following objectives:
1. To evaluate the eye cream impact on undereye dark circles, undereye puffiness, fine lines and wrinkles periorbital eye area, and overall appearance periorbital eye area, as evaluated by investigator clinical grading, chromameter, VISIA clinical photography, and subjec...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Females in good general health
- • With Fitzpatrick Skin Type I - VI
- • Moderate to severe under eye dark circles
- • Moderate undereye puffiness
- • Mild to moderate fine lines and wrinkles
- Exclusion Criteria:
- • Subjects who have used retinol or eye cream / serum 7 days prior to study commencement
- • Nursing, pregnant, or planning a pregnancy during this study
- • Having a health condition and / or pre-existing or dormant dermatologic disease on the face
About Revision Skincare
Revision Skincare is a leading clinical trial sponsor dedicated to advancing the science of skincare through innovative research and development. With a commitment to quality and efficacy, the company focuses on formulating advanced skincare solutions that are backed by rigorous clinical studies. Revision Skincare collaborates with healthcare professionals and researchers to ensure that their products meet the highest standards of safety and effectiveness, ultimately aiming to enhance the health and appearance of skin for diverse patient populations. Through its comprehensive approach to clinical trials, Revision Skincare strives to provide evidence-based solutions that empower individuals to achieve their skincare goals.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Teaneck, New Jersey, United States
Patients applied
Trial Officials
Anna Hardy
Study Director
Validated Claim Support
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials